Gilead Sciences, Inc.'s Form 4 filing
Xilio Therapeutics, Inc. (XLO) · filed Jun 6, 2025
- Accession no.
- 0001062993-25-011170
- Filed
- Jun 6, 2025
- Trade date
- Jun 5, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 derivative transactions. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gilead Sciences, Inc.CIK 0000882095 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2025 | Common Stock | PPurchaseAcquired | +13,335,000 | –F1 | – | 23,310,266 | Direct | |
| Jun 5, 2025 | Common Stock | PPurchaseAcquired | +13,335,000 | –F1 | – | 13,335,000 | Direct | |
| Jun 5, 2025 | Common Stock | PPurchaseAcquired | +13,335,000 | –F1 | – | 13,335,000 | Direct | |
| Jun 5, 2025 | Common Stock | PPurchaseAcquired | +13,335,000 | –F1 | – | 13,335,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each Prefunded Warrant was acquired together with an accompanying Series A Warrant, Series B Warrant and Series C Warrant at a combined offering price of $0.7499. A holder of any such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").
Referenced by the price of 4 transactions in Table II.